Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03101475
Title Synergism of Immunomodulation and Tumor Ablation (ILOC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC
Indications

colorectal cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries FRA | DEU | AUT


No variant requirements are available.